Table of Contents
ISRN Cardiology
Volume 2011, Article ID 675638, 6 pages
http://dx.doi.org/10.5402/2011/675638
Review Article

Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis

1Department of Cardiology, James A Lovell Federal Health Center/Chicago Medical School, 3001 Green Bay Road, North Chicago, IL 60064, USA
2Department of Medicine, Saint Louis University Medical School, 1402 South Grand, St. Louis, MO 63104, USA

Received 17 February 2011; Accepted 1 April 2011

Academic Editors: A. R. Galassi, S. Hirohata, and S.-J Park

Copyright © 2011 Rohit S. Loomba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. U. Choi, S. W. Rha, K. Y. Chen et al., “Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention,” Circulation Journal, vol. 73, no. 12, pp. 2229–2235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. U. Kim, D. K. Kim, S. H. Seol et al., “Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion,” Clinical Cardiology, vol. 33, no. 6, pp. 340–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Chevalier, C. Di Mario, F. J. Neumann et al., “A randomized, controlled, mutlicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries,” Journal of the American Collage of Cardiology, vol. 1, no. 5, pp. 524–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. W. Lee, D. W. Park, S. H. Lee et al., “Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction,” American Journal of Cardiology, vol. 104, no. 10, pp. 1370–1376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Cicek, H. Pekdemir, C. Haberal et al., “Two year outcome of turkish patients treated with zotarolimus versus paclitaxel elutings stents in an unselected population with coronary artery disease in the real world: a prospective non randomized registry in southern turkey,” International Journal of Medical Sciences, vol. 8, no. 1, pp. 68–73, 2011. View at Google Scholar
  6. J. W. Moses, M. B. Leon, J. J. Popma et al., “Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery,” The New England Journal of Medicine, vol. 349, no. 14, pp. 1315–1323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. G. J. Laarman, M. J. Suttorp, M. T. Dirksen et al., “Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention,” The New England Journal of Medicine, vol. 355, no. 11, pp. 1105–1113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Spaulding, P. Henry, E. Teiger et al., “Sirolimus-eluting versus uncoated stents in acute myocardial infarction,” The New England Journal of Medicine, vol. 355, no. 11, pp. 1093–1104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Menichelli, A. Parma, E. Pucci, R. Fiorilli et al., “Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction,” Journal of the American College of Cardiology, vol. 49, no. 19, pp. 1924–1930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. W. Stone, J. W. Moses, S. G. Ellis et al., “Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 998–1008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Kastrati, J. Mehilli, J. Pache et al., “Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 1030–1039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. O. C. Marroquin, F. Selzer, S. R. Mulukutla et al., “A comparison of bare-metal and drug-eluting stents for off-label indications,” The New England Journal of Medicine, vol. 358, no. 4, pp. 342–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Carlsson, S. K. James, J. Lindbäck et al., “Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria,” Journal of the American College of Cardiology, vol. 53, no. 16, pp. 1389–1398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Sollott, L. Cheng, R. R. Pauly et al., “Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat,” The Journal of Clinical Investigation, vol. 95, no. 4, pp. 1869–1876, 1995. View at Google Scholar · View at Scopus
  15. P. B. Schiff and S. B. Horwitz, “Taxol stabilizes microtubules in mouse fibroblast cells,” Proceedings of the National Academy of Sciences, vol. 77, no. 3, pp. 1561–1565, 1980. View at Google Scholar · View at Scopus
  16. D. W. Park, Y. H. Kim, S. C. Yun et al., “Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel- eluting stents for coronary revascularization,” The Journal of The American College of Cardiology, vol. 56, no. 15, pp. 1187–1195, 2010. View at Google Scholar
  17. L. E. Burke, J. Choo, E. Music et al., “PREFER study: a randomized clinical trial testing treatment preference and two dietary options in behavioral weight management—rationale, design and baseline characteristics,” Contemporary Clinical Trials, vol. 27, no. 1, pp. 34–48, 2006. View at Publisher · View at Google Scholar · View at Scopus